Episodes (Page 6)
✨
Dr. Linda Marbán discusses the future of exosome science.
Linda Marban
✨
Pascal Touchon discusses Atara Biotherapeutics' allogeneic approval.
Pascal Touchon
✨
Romesh Subramanian defines RNA exon editing.
✨
Paolo Siciliano on automating CGT manufacturing processes.
Paolo Siciliano
✨
Andy Ramelmeir explains Sangamo's in-house manufacturing strategy.
Andy Ramelmeier
✨
Miguel Forte provides a 2023 market outlook for CGT.
Miguel Forte
✨
Robert Sexton addresses CMC challenges and scale-up in CGT.
✨
Dr. Peter Marks discusses FDA's CBER innovation areas.
Peter Marks
✨
Dr. Robert Hollingsworth on NK and macrophage immunotherapies.
Robert Hollingsworth
✨
Seth Ettenberg discusses BlueRock's Parkinson's trial.
Seth Ettenberg
✨
Orgenesis CEO Vered Caplan discusses manufacturing cell and gene therapies at the point of care.
Vered Caplan
✨
Capstan Therapeutics CEO Laura Shawver explains in vivo CAR therapies using mRNA and LNP delivery.
Laura Shawver
✨
PepGen's Dr. Michelle Mellion discusses delivering oligonucleotide therapies for neuromuscular diseases.
Michelle Mellion
✨
BridgeBio's Adora Ndu explains the PDUFA VII reauthorization and its impact on the cell and gene sector.
Adora Ndu
✨
Arrowhead Pharmaceuticals' Javier San Martin compares RNAi and CRISPR gene silencing technologies.
Javier San Martin
✨
Kite Pharma's Will Junker addresses challenges in manufacturing capacity planning for cell therapies.
✨
Novartis Gene Therapies President Chris Fox discusses commercialization strategies for gene therapies.
✨
Sernova Corp. CEO Philip Toleikis details a stem cell-derived treatment for Type 1 Diabetes.
Philip Toleikis
✨
Center for Breakthrough Medicines VPs share best practices for partnering with a CDMO.
Avi Nandi
Emily Moran
✨
CAR-T pioneer Dr. Carl June discusses the current state and future of CAR-T therapy.
Carl June